Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease

NCT04392414 is registered in ClinicalTrials.gov with Federal Research Clinical Center of Federal Medical & Biological Agency, Russia as lead sponsor.

NCT NCT04392414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04392414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease
Lead sponsor
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2020
Completion date
September 23, 2020
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19